Prevention of Glucocorticoid-Induced Osteoporosis in Immunobullous Diseases With Alendronate
نویسندگان
چکیده
منابع مشابه
Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.
OBJECTIVE To evaluate the efficacy and safety of oral alendronate sodium therapy once daily in preventing glucocorticoid-induced bone loss in patients with immunobullous skin diseases treated with long-term glucocorticoid therapy. DESIGN A 12-month randomized, double-blind, placebo-controlled trial. SETTING A tertiary referral dermatology center in Singapore. PARTICIPANTS Patients newly d...
متن کاملAlendronate prevents glucocorticoid-induced osteoporosis in patients with rheumatic diseases
Glucocorticoid-induced osteoporosis (GIOP) is a serious problem for patients with rheumatic diseases requiring long-term glucocorticoid treatment. Alendronate, a bisphosphonate, has been recommended in the prevention of GIOP. However, the efficacy and safety of alendronate in preventing GIOP remains controversial. We performed a meta-analysis to investigate the efficacy and safety of alendronat...
متن کامل[Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol].
OBJECTIVE To explore the relation of changes in measures of bone turnover and changes in bone mineral density (BMD) of the lumbar spine and total hip over 18 months in a double-blinded, randomized trial, comparing the effect of alfacalcidol (101 patients) versus alendronate (100 patients) on BMD in patients who recently started treatment with glucocorticoids for various rheumatic diseases. ME...
متن کاملAlendronate or alfacalcidol in glucocorticoid-induced osteoporosis.
BACKGROUND Treatment with glucocorticoids is associated with bone loss starting soon after therapy is initiated and an increased risk of fracture. METHODS We performed a randomized, double-placebo, double-blind clinical trial of 18 months' duration among patients with a rheumatic disease who were starting glucocorticoids at a daily dose that was equivalent to at least 7.5 mg of prednisone. A ...
متن کامل[Glucocorticoid-induced osteoporosis and rheumatic diseases. Pathogenesis, prevention and treatment].
Glucocorticoids (GC) are diffusely used to treat a wide variety of inflammatory and autoimmune disorders, including rheumatic diseases. GC-induced osteoporosis (GIO) is the most common and serious side-effect for patients receiving GC. Loss of bone mineral density (BMD) is greatest in the first few months of GC use; fracture (Fx) risk is significantly increased at the spine and hip on doses eve...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Archives of Dermatology
سال: 2012
ISSN: 0003-987X
DOI: 10.1001/archdermatol.2011.354